Cell Cycle · 2011 · 39 citations · 37 references
Life SciencesMolecular BiologyOncologyApoptosisDna RepairMolecular OncologyApoptosis In CancerCancer TranscriptomicsCheckpoint Inhibitor TherapyDna DamageDna Damage SignalingDna Damage-induced ApoptosisCheckpoint Inhibitor CombinationsDna Damage Response PathwaysDna Damage ResponsesDna Damage-induced Cell DeathG2 Checkpoint ArrestParp InhibitionPoly Adp-ribose Polymerase InhibitorsTopotecan Therapy
Targeting DNA repair with poly(ADP-ribose) polymerase (PARP) inhibitors has shown a broad range of anti-tumor activity in patients with advanced malignancies with and without BRCA deficiency. It remains unclear what role p53 plays in response to PARP inhibition in BRCA-proficient cancer cells treated with DNA damaging agents. Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. In contrast, topotecan alone induces the G1/S checkpoint pathway in p53-wildtype lines and not in p53-mutant cells. These responses are coupled with G2/G1 checkpoint effectors p21(CDKN1A) upregulation, and Chk1 and Chk2 activation. The drug combination enhances G2 cell cycle arrest, apoptosis and a marked increase in cell death relative to topotecan alone in p53-wildtype and p53-mutant or -null cells. We also show that the checkpoint kinase inhibitor UCN-01 abolishes the G2 arrest induced by the veliparib and topotecan combination and further increases cell death in both p53-wildtype and -mutant cells. Collectively, PARP inhibition by veliparib enhances DDR and cell death in BRCA-proficient cancer cells in a p53-dependent and -independent fashion. Abrogating the cell-cycle arrest induced by PARP inhibition plus chemotherapeutics may be a strategy in the treatment of BRCA-proficient cancer.
37
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Bert Vogelstein, David P. Lane, Arnold J. Levine · Nature · 2000 · 6.6K citations
Requirement for p53 and p21 to Sustain G <sub>2</sub> Arrest After DNA Damage
Fred Bunz, Annie Dutriaux, Christoph Lengauer et al. · Science · 1998 · 2.8K citations
Karen A. Gelmon, Marc Tischkowitz, Helen Mackay et al. · The Lancet Oncology · 2011 · 1.1K citations
Medicine, Gynecology, Oncology +17